Ferda Cevikbas1, Joao M Braz2, Xidao Wang3, Carlos Solorzano3, Mathias Sulk4, Timo Buhl5, Martin Steinhoff6, Allan I Basbaum3. 1. Department of Anatomy, University California San Francisco, San Francisco, Calif; Department of Dermatology, University California San Francisco, San Francisco, Calif. 2. Department of Anatomy, University California San Francisco, San Francisco, Calif. Electronic address: joao.braz2@ucsf.edu. 3. Department of Anatomy, University California San Francisco, San Francisco, Calif. 4. Department of Dermatology, University California San Francisco, San Francisco, Calif; Department of Dermatology, University Hospital Münster, Münster, Germany. 5. Department of Dermatology, University California San Francisco, San Francisco, Calif; Department of Dermatology, University Medical Center Göttingen, Göttingen, Germany. 6. Department of Dermatology, University California San Francisco, San Francisco, Calif; Department of Dermatology, University College Dublin, Dublin, Ireland; Charles Institute for Translational Dermatology, University College Dublin, Dublin, Ireland; Department of Dermatology and Venerology, Hamad Medical Corporation, Qatar University, Doha, Qatar; School of Medicine, Qatar University, Doha, Qatar.
Abstract
BACKGROUND: Despite recent insights into the pathophysiology of acute and chronic itch, chronic itch remains an often intractable condition. Among major contributors to chronic itch is dysfunction of spinal cord gamma aminobutyric acidergic (GABAergic) inhibitory controls. OBJECTIVES: We sought to test the hypothesis that selective GABA agonists as well as cell transplant-derived GABA are antipruritic against acute itch and in a transgenic mouse model of atopic dermatitis produced by overexpression of the TH2 cell-associated cytokine, IL-31 (IL-31Tg mice). METHODS: We injected wild-type and IL-31Tg mice with combinations of GABA-A (muscimol) or GABA-B (baclofen) receptor agonists 15 to 20 minutes prior to injection of various pruritogens (histamine, chloroquine, or endothelin-1) and recorded spontaneous scratching before and after drug administration. We also tested the antipruritic properties of intraspinal transplantation of precursors of GABAergic interneurons in the IL-31Tg mice. RESULTS: Systemic muscimol or baclofen are antipruritic against both histamine-dependent and -independent pruritogens, but the therapeutic window using either ligand alone was very small. In contrast, combined subthreshold doses of baclofen and muscimol produced a significant synergistic antipruritic effect, with no sedation. Finally, transplant-mediated long-term enhancement of GABAergic signaling not only reduced spontaneous scratching in the IL-31Tg mice but also dramatically resolved the associated skin lesions. CONCLUSIONS: Although additional research is clearly needed, existing approved GABA agonists should be considered in the management of chronic itch, notably atopic dermatitis.
BACKGROUND: Despite recent insights into the pathophysiology of acute and chronic itch, chronic itch remains an often intractable condition. Among major contributors to chronic itch is dysfunction of spinal cord gamma aminobutyric acidergic (GABAergic) inhibitory controls. OBJECTIVES: We sought to test the hypothesis that selective GABA agonists as well as cell transplant-derived GABA are antipruritic against acute itch and in a transgenic mouse model of atopic dermatitis produced by overexpression of the TH2 cell-associated cytokine, IL-31 (IL-31Tg mice). METHODS: We injected wild-type and IL-31Tg mice with combinations of GABA-A (muscimol) or GABA-B (baclofen) receptor agonists 15 to 20 minutes prior to injection of various pruritogens (histamine, chloroquine, or endothelin-1) and recorded spontaneous scratching before and after drug administration. We also tested the antipruritic properties of intraspinal transplantation of precursors of GABAergic interneurons in the IL-31Tg mice. RESULTS: Systemic muscimol or baclofen are antipruritic against both histamine-dependent and -independent pruritogens, but the therapeutic window using either ligand alone was very small. In contrast, combined subthreshold doses of baclofen and muscimol produced a significant synergistic antipruritic effect, with no sedation. Finally, transplant-mediated long-term enhancement of GABAergic signaling not only reduced spontaneous scratching in the IL-31Tg mice but also dramatically resolved the associated skin lesions. CONCLUSIONS: Although additional research is clearly needed, existing approved GABA agonists should be considered in the management of chronic itch, notably atopic dermatitis.
Authors: João M Bráz; Reza Sharif-Naeini; Daniel Vogt; Arnold Kriegstein; Arturo Alvarez-Buylla; John L Rubenstein; Allan I Basbaum Journal: Neuron Date: 2012-05-24 Impact factor: 17.173
Authors: Stacey R Dillon; Cindy Sprecher; Angela Hammond; Janine Bilsborough; Maryland Rosenfeld-Franklin; Scott R Presnell; Harald S Haugen; Mark Maurer; Brandon Harder; Janet Johnston; Susan Bort; Sherri Mudri; Joseph L Kuijper; Tom Bukowski; Pamela Shea; Dennis L Dong; Maria Dasovich; Francis J Grant; Luann Lockwood; Steven D Levin; Cosette LeCiel; Kim Waggie; Heather Day; Stavros Topouzis; Janet Kramer; Rolf Kuestner; Zhi Chen; Don Foster; Julia Parrish-Novak; Jane A Gross Journal: Nat Immunol Date: 2004-06-06 Impact factor: 25.606
Authors: T Follansbee; T Akiyama; M Fujii; A Davoodi; M Nagamine; M Iodi Carstens; E Carstens Journal: J Neurophysiol Date: 2018-06-27 Impact factor: 2.714
Authors: Joao M Braz; Todd Dembo; Alexandra Charruyer; Ruby Ghadially; Marlys S Fassett; Allan I Basbaum Journal: Proc Natl Acad Sci U S A Date: 2021-02-23 Impact factor: 11.205
Authors: Jing Huang; Erika Polgár; Hans Jürgen Solinski; Santosh K Mishra; Pang-Yen Tseng; Noboru Iwagaki; Kieran A Boyle; Allen C Dickie; Mette C Kriegbaum; Hendrik Wildner; Hanns Ulrich Zeilhofer; Masahiko Watanabe; John S Riddell; Andrew J Todd; Mark A Hoon Journal: Nat Neurosci Date: 2018-03-19 Impact factor: 24.884